How do Vraylar (cariprazine) and Rexulti (brexpiprazole) compare regarding mechanism of action, dosing, half‑life, and side‑effect profile?

Comparison of Vraylar (Cariprazine) and Rexulti (Brexpiprazole)

Both Vraylar and Rexulti are dopamine D2/D3 receptor partial agonists with distinct pharmacological profiles that translate into clinically meaningful differences: Vraylar demonstrates superior efficacy for negative symptoms and lower weight gain risk but higher akathisia rates, while Rexulti offers lower akathisia risk with moderate weight gain and broader FDA indications including agitation in dementia. 1, 2, 3

Mechanism of Action

Both agents function as partial agonists at dopamine D2 and D3 receptors, but with critical pharmacodynamic distinctions:

• Vraylar (cariprazine) has the highest affinity for the dopamine D3 receptor among all dopamine partial agonists, which may contribute to its efficacy in treating negative symptoms of schizophrenia 3, 4
• Rexulti (brexpiprazole) has lower intrinsic dopamine D2 activity compared to aripiprazole and higher affinity for serotonin 5-HT1A and 5-HT2A receptors 2, 3, 4
• Brexpiprazole acts as a partial agonist at 5-HT1A, D2, and D3 receptors and as an antagonist at 5-HT2A, 5-HT2B, 5-HT7, and multiple alpha-adrenergic receptors 2
• Brexpiprazole exhibits stronger antihistaminic activity (H1 receptor affinity 19 nM) compared to cariprazine, which translates to greater sedative effects and potentially lower akathisia risk 2, 5

Dosing and Administration

Vraylar (Cariprazine)

• Schizophrenia (adults): Start 1.5 mg once daily, increase to 3 mg on Day 2, range 1.5-6 mg daily, maximum 6 mg daily 1
• Schizophrenia (pediatric 13-17 years): Start 0.5 mg daily, increase to 1.5 mg on Day 3, range 1.5-4.5 mg daily, maximum 4.5 mg daily 1
• Bipolar mania (adults): Start 1.5 mg daily, increase to 3 mg on Day 2, range 3-6 mg daily 1
• Bipolar depression (adults): Start 1.5 mg daily, may increase to 3 mg on Day 15, maximum 3 mg daily 1
• MDD adjunctive (adults): Start 1.5 mg daily, may increase to 3 mg on Day 15, maximum 3 mg daily 1

Rexulti (Brexpiprazole)

• Schizophrenia: Titrate to target dose over 4 days, typical maintenance 2-4 mg once daily 2
• MDD adjunctive: Start 0.5-1 mg daily, target 2 mg daily (titration intervals <14 days result in higher adverse reaction rates) 2
• Peak plasma concentrations occur within 4 hours, steady-state achieved in 10-12 days 2
• Can be administered with or without food (95% oral bioavailability) 2

Half-Life and Pharmacokinetics

This represents the most clinically significant difference between the two agents:

• Vraylar: Extremely long half-life requiring weeks for dose adjustments to be fully reflected in plasma; prescribers must monitor patients for adverse reactions and treatment response for several weeks after starting or changing doses 1
• Rexulti: Terminal elimination half-life of 91 hours for brexpiprazole and 86 hours for its major metabolite DM-3411 2
• Both drugs are metabolized primarily by CYP3A4 and CYP2D6 enzymes 2
• Brexpiprazole reaches steady-state in 10-12 days, while cariprazine requires significantly longer due to its extended half-life 2, 3

Side Effect Profile

Akathisia

• Cariprazine has the highest akathisia risk among dopamine partial agonists, while brexpiprazole has the lowest risk 3, 6
• The lower D2/D3 receptor activation-to-blocking ratio of brexpiprazole compared to cariprazine translates into lower akathisia rates 5
• Akathisia typically occurs in the first few weeks of treatment and is generally low-to-moderate severity 3

Weight Gain

• Cariprazine: Low weight gain risk 3, 6
• Brexpiprazole: Moderate weight gain risk, higher than cariprazine but lower than olanzapine 3, 6

Metabolic Effects

• Both agents have favorable cardiometabolic side-effect profiles compared to older antipsychotics 7
• Low risk of hyperprolactinemia with both agents due to partial dopamine agonism; prolactin levels may actually decrease in some patients 3
• Neither drug significantly prolongs QTc interval at therapeutic doses 2

Other Adverse Effects

• Sedation risk: Low for both agents, though brexpiprazole's stronger antihistaminic activity may produce more sedation 3, 5
• Insomnia and nausea: Low risk with both agents 3
• Sexual dysfunction: Likely low risk due to low hyperprolactinemia rates 3
• Extrapyramidal symptoms: Low risk overall, though cariprazine carries higher risk than brexpiprazole 3, 6

Clinical Efficacy Considerations

Comparative Effectiveness

• For treatment-resistant depression: Aripiprazole demonstrates superior efficacy over both brexpiprazole and cariprazine, with maximum effective doses at 5.5 mg, 1.6 mg, and 1.5 mg respectively 8
• For negative symptoms: Cariprazine shows specific efficacy for primary negative symptoms of schizophrenia, likely related to its high D3 receptor affinity 9, 6
• For functional outcomes: In real-world MDD studies, cariprazine demonstrated significantly greater reductions in disability claims, days, and costs compared to brexpiprazole 10
• Healthcare utilization: Cariprazine was associated with significantly fewer all-cause and MDD-related inpatient stays compared to brexpiprazole, aripiprazole, and quetiapine 11

FDA-Approved Indications

Both drugs share schizophrenia and MDD adjunctive therapy indications, but differ in:

• Vraylar: Approved for bipolar mania, mixed episodes, and bipolar depression 1
• Rexulti: Approved for agitation associated with dementia due to Alzheimer's disease (unique among dopamine partial agonists) 2

Clinical Decision-Making Algorithm

When switching from a D2 partial agonist that fails first-line treatment, the 2025 Lancet Psychiatry guidelines recommend switching to amisulpride, risperidone, paliperidone, or olanzapine (with samidorphan or metformin) rather than another partial agonist 12

Choose Vraylar when:

• Negative symptoms are prominent (D3 receptor affinity advantage) 9, 6
• Weight gain must be minimized 3
• Patient can tolerate higher akathisia risk 3
• Bipolar depression or mania requires treatment 1

Choose Rexulti when:

• Akathisia risk must be minimized (lowest among partial agonists) 3, 5
• Agitation in dementia requires treatment 2
• Moderate weight gain is acceptable 3
• Faster dose titration is needed (shorter half-life) 2

Critical Pitfalls

• Do not expect rapid dose adjustments with Vraylar: The extremely long half-life requires waiting several weeks to assess full therapeutic response or adverse effects after any dose change 1
• Avoid rapid titration with Rexulti in MDD: Titration intervals less than 14 days result in significantly higher adverse reaction rates 2
• Monitor for impulse control disorders: While primarily reported with aripiprazole, partial dopamine agonism theoretically carries this risk (no reports yet with brexpiprazole or cariprazine) 3
• Consider CYP2D6 metabolizer status: Poor metabolizers or those on strong CYP3A4/2D6 inhibitors require dose adjustments for both agents 2
• Discontinuation rates are low: Both agents demonstrate good overall tolerability in pivotal trials 3